ChemoCentryx Determines Not to Proceed with Public Offering of Common Stock
September 27 2018 - 10:20PM
ChemoCentryx, Inc. (the "Company" or "ChemoCentryx") (Nasdaq:CCXI)
announced today that it will not conclude an offering of shares of
its common stock as announced on Wednesday, September 26, 2018. The
Company believes that culmination of terms representing the best
interests of its stockholders is not to be achieved at the current
time.
The offering was being made pursuant to an effective shelf
registration statement filed with the Securities and Exchange
Commission on April 28, 2016. This press release shall not
constitute an offer to sell, or the solicitation of an offer to
buy, nor shall there be any sale of, these securities in any state
or other jurisdiction in which such offer, solicitation or sale
would be unlawful prior to the registration or qualification under
the securities laws of such state or other jurisdiction.
About ChemoCentryx
ChemoCentryx is a biopharmaceutical company developing new
medications targeted at inflammatory and autoimmune diseases and
cancer. ChemoCentryx targets the chemokine and
chemoattractant systems to discover, develop and commercialize
orally-administered therapies.
CCXI - G
Contacts:
Susan M. KanayaExecutive Vice President, Chief Financial and
Administrative Officerinvestor@chemocentryx.com
Media:Stephanie Tomei408.234.1279
Investors:Burns McClellan, Inc.Steve
Klass212.213.0006sklass@burnsmc.com
Source: ChemoCentryx, Inc.
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Aug 2024 to Sep 2024
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Sep 2023 to Sep 2024